Zelboraf gets EU go-ahead from CHMP
This article was originally published in Scrip
Executive Summary
Roche (Genentech)'s novel treatment for melanoma Zelboraf (vemurafenib) has taken a major step forward to EU approval with a positive opinion from the CHMP at its latest meeting.